Skip to main content

Augmentation Cystoplasty

Augmentation cystoplasty (AC) is the gold-standard operation for increasing bladder capacity and lowering storage pressure in patients with refractory neurogenic or non-neurogenic bladder dysfunction when appropriate less invasive treatment is ineffective, unsuitable, or not tolerated.[1][2][3][4] The modern operation is usually a detubularized ileocystoplasty: a short ileal segment is isolated, opened along its antimesenteric border, reconfigured into a low-pressure patch, and anastomosed to a widely bivalved bladder.[1][8][9]

The decision to augment is not just about continence. For the reconstructive urologist, the core indication is an unsafe reservoir: high storage pressures, poor compliance, and progressive upper-tract deterioration despite optimized conservative therapy.[2][4][5] AC is durable and effective, but it exchanges one disease state for a lifelong reconstructed system that requires reliable emptying (often clean intermittent catheterization [CIC]), mucus management, metabolic surveillance, and vigilance for stones, perforation, and late malignancy.[1][17][19][20]

EAU 2026 recommends augmentation for low compliance and/or refractory neurogenic detrusor overactivity after less invasive options fail. Lifelong follow-up is required; CIC may be necessary. Evidence for many technical comparisons remains observational.[33]

Indications​

Augmentation cystoplasty is indicated when the bladder remains hostile despite appropriate medical and minimally invasive management:

IndicationPractical meaning
Refractory low-capacity / poorly compliant bladderFailure or intolerance of appropriate storage therapy and optimized emptying; botulinum toxin is considered where suitable[1][4]
Unsafe storage pressurePersistent detrusor leak point or storage pressure high enough to threaten the upper tracts[2][4]
Upper-tract deteriorationHydronephrosis, vesicoureteral reflux, recurrent pyelonephritis, or declining renal function attributable to a hostile bladder[2][5][17]
Refractory incontinenceIncontinence despite CIC and medical therapy, especially in neurogenic bladder patients with salvageable outlet function or a plan for concomitant outlet surgery[2][17][18]

Common underlying disease states include spina bifida, spinal cord injury, posterior urethral valves, bladder exstrophy, genitourinary tuberculosis, and severe idiopathic detrusor overactivity or fibrosis.[1][3][6]

Practical contraindications​

Selection depends on disease, renal reserve, bowel health, and a workable lifelong care plan:

  • Significant renal insufficiency / azotemia — increases the consequences of bowel-mediated solute exchange, especially with colon and ileum[2][7][23]
  • No dependable emptying and irrigation plan — patients or caregivers must be able to perform catheterization if needed; spontaneous voiding cannot be guaranteed, and an inaccessible or unmanageable reservoir risks retention, stones, and perforation[1][4]
  • Short bowel, major prior bowel resection, or active inflammatory bowel disease — may limit usable segment choice or make bowel incorporation unacceptable[2][3]
  • Untreated outlet obstruction or unresolved outlet incompetence — capacity alone does not solve a hostile outlet; many patients need a concomitant outlet procedure[1][16]

Preoperative Decision Framework​

Before offering AC, the reconstructive question is whether the patient needs a bigger low-pressure reservoir, a different outlet, or an incontinent bypass altogether.

The classic augmentation candidate​

  • Safe renal reserve, or at least enough reserve to tolerate bowel incorporation
  • Proven low-capacity / poor-compliance bladder on urodynamics
  • Failure of optimized medical therapy and usually botulinum toxin
  • Patient or caregiver ability to catheterize if required, with frequency tailored to urine production, capacity, pressures, and residuals
  • Willingness to irrigate mucus and accept lifelong follow-up[1][4]

The patient who may be better served by diversion​

The alternative is often not another bladder salvage maneuver but an incontinent diversion. In patients unable to catheterize, medically fragile patients, or those with recurrent complications from a hostile native bladder, ileal conduit or ileovesicostomy may be more rational than augmentation.[4][21]

Required preoperative workup​

  • History focused on catheterization ability, continence goals, bowel history, prior abdominal surgery, and prior radiation or tuberculosis
  • Urodynamics documenting low capacity and/or poor compliance
  • Upper-tract imaging for hydronephrosis or reflux
  • Baseline renal function and electrolytes
  • Counseling that augmentation is a lifelong reconstructed state, not a one-time cure[1][2][4]

Technique Overview​

Gold standard: enterocystoplasty​

Enterocystoplasty remains the reference standard because bowel provides a large compliant patch that can be configured into a low-pressure reservoir.[1][3] The key technical principle is detubularization: the isolated bowel is opened so that coordinated tubular contractions are reduced; residual pressure waves may persist.[8][9]

Core steps of augmentation cystoplasty​

  1. Mobilize and widely bivalve the bladder to create a broad native plate.
  2. Isolate the chosen bowel segment with preservation of mesenteric blood supply.
  3. Re-establish bowel continuity.
  4. Detubularize and reconfigure the segment into a patch or cup.
  5. Anastomose the bowel patch to the opened bladder in a tension-free, watertight fashion.
  6. Add concomitant procedures as needed: catheterizable channel, ureteral reimplantation, or outlet surgery.[1][8][16]

Segment Selection and Configuration​

TechniqueReconstructive roleKey advantagesMain tradeoffs
IleocystoplastyStandard modern augmentationFamiliar segment, reliable mesentery, excellent low-pressure dynamics after detubularization[1][8][9]Hyperchloremic metabolic acidosis, mucus, B12 deficiency risk with longer segments[22][23]
SigmoidocystoplastyAlternative when colon is preferredCan reduce small-bowel handling; cup-patch configuration outperforms tubular colon[8][9]Similar acidosis / mucus issues; colon can be bulky in a deep pelvis
Ileocecal cystoplastyUseful when ureteral reach is difficultHelpful when a wide gap exists between ureters and bladder or when massively dilated ureters require implantation[9]More complex bowel work; same bowel-related surveillance burden
GastrocystoplastyHistorical niche, mostly renal-insufficiency logicLower chloride reabsorption, less mucus, lower stone burden, avoids further small-bowel resection[3][10][11]Hematuria-dysuria syndrome, metabolic alkalosis, concerning malignancy signal[10][11][28]

Why ileum remains the default​

Ileum balances reach, ease of detubularization, and dependable reservoir dynamics better than most alternatives. A typical segment length is 15–40 cm, but the exact length is driven by bladder plate size, target capacity, mesenteric reach, and whether a concomitant channel is needed.[1][8][9]

Configuration matters more than segment name​

The major technical lesson from the classic enterocystoplasty literature is that detubularized reconfigured bowel behaves better than intact tubular bowel. Low-pressure storage, continence, and perforation avoidance all improve when the augment is opened and refashioned rather than sewn in as a tube.[8][9][20]

Alternative and Salvage Augmentation Strategies​

Autoaugmentation​

Autoaugmentation (vesicomyotomy / detrusorectomy) removes detrusor over the dome while leaving the urothelium intact, allowing the mucosa to bulge outward as a pseudodiverticulum.[12][13] It avoids bowel morbidity and does not burn the bridge to later enterocystoplasty, but its effect on capacity and compliance is generally more modest and less durable than bowel-based augmentation.[12][13]

Seromuscular colocystoplasty lined with urothelium (SCLU)​

SCLU combines autoaugmentation with a demucosalized colonic patch placed over preserved urothelium, aiming to avoid bowel-mucosa complications such as mucus and metabolic exchange.[8] Conceptually attractive, but used in selected centers rather than as mainstream reconstructive practice.

Ureterocystoplasty​

Ureterocystoplasty uses a suitably dilated ureter to augment the bladder without bowel. Many reported operations use the ureter of a poorly functioning renal unit; selected approaches preserve the kidney with a separate drainage reconstruction.[14] It is an elegant option when the anatomy is already available, but applicability is limited by the need for the right ureteral scenario.

Robot-assisted augmentation​

Robot-assisted laparoscopic ileocystoplasty has been reported in both adult and pediatric series, often combined with Mitrofanoff creation.[15][16] Potential recovery and cosmetic benefits must be weighed against operative complexity and time. The cited reports do not establish superior pain, length of stay, or long-term outcomes over open augmentation.

Concomitant Procedures​

Augmentation often succeeds only when paired with additional reconstructive steps:

Concomitant procedureWhy it is added
Continent catheterizable channel (Mitrofanoff / appendicovesicostomy)For patients who cannot catheterize the native urethra reliably[1][16]
Ureteral reimplantationFor selected anatomic obstruction or ureteral reconstruction needs; high-pressure reflux can improve with augmentation alone. EAU notes uncertainty about routine simultaneous reimplantation for high-grade reflux[33][1][5][9]
Outlet procedureSling, AUS, bladder-neck reconstruction, or bladder-neck closure when continence will not be achieved by augmentation alone[1][16][18]

This is why augmentation belongs within a bladder reconstruction framework rather than as an isolated storage operation. In many patients the real construct is a rebuilt reservoir plus a rebuilt outlet.

Outcomes​

Reservoir function​

Across modern series and reviews, AC reliably increases bladder capacity and compliance while reducing storage pressure.[1][17][19] That physiologic change — not merely the larger bladder size — is what protects the kidneys.

Continence​

Reported continence rates usually fall between 78% and 95%, especially when concomitant outlet procedures are used appropriately.[8][17][18] Reported success varies because some series define success as daytime dryness, others as social continence, and others include patients with catheterizable channels or AUS.

Upper-tract preservation​

Hydronephrosis and reflux improve or resolve in most patients, and renal function often stabilizes when the reservoir is made safe early enough.[5][17]

Durability​

In Szymanski et al.’s retrospective cohort of 413 patients with spina bifida, estimated 10-year conversion to diversion was 2.7%, but any reoperation was 43.9%. These are time-to-event estimates from a mixed-era cohort; in the 222-patient modern subgroup, corresponding estimates were 4.0% and 46.0%.[20]

Quality of life​

Most patients report better continence, greater independence, and relief of upper-tract anxiety after successful augmentation, although this benefit is inseparable from the burden of CIC, irrigation, stone surveillance, and reintervention.[1][19]

Complications​

Augmentation cystoplasty is effective but not low-maintenance. The dominant long-term complications are below.

Stones​

Bladder or reservoir stones are the most common late complication, with an estimated 28.2% 10-year risk in the 413-patient Szymanski spina bifida cohort (32.9% in its modern subgroup). Chang et al. reported stones in 8/22 patients (36.4%) over mean follow-up 13.4 years; this is not a 10-year actuarial estimate.[17][20] Risks are amplified by mucus, bacteriuria, continent catheterizable channels, and exstrophy anatomy. Recurrence is common.

Perforation​

Reservoir perforation is a potentially fatal late event. In Szymanski et al.’s spina bifida cohort, estimated 10-year risk was 9.6% with detubularized reconfigured ileocystoplasty versus 23.7% without it, and 8.8% in the modern subgroup. These observational estimates should not be generalized to all augmentation populations or interpreted as randomized technique comparisons.[8][20]

Chronic bacteriuria and symptomatic UTI​

Asymptomatic bacteriuria is common in catheterized augmented systems and should not routinely be screened for or treated in stable NLUTD patients. Assess new symptoms for UTI or pyelonephritis; bacteriuria alone does not establish infection.[1][19]

Mucus​

Mucus production is inherent to bowel incorporation and is not a trivial nuisance. It contributes to catheter blockage, irrigation burden, and stone formation.[1][21]

Bowel morbidity and reoperation​

Small bowel obstruction occurs in a meaningful minority, and overall reoperation rates are high. In the Szymanski spina bifida cohort, 44% required at least one additional surgery within 10 years.[19][20]

Metabolic and Nutritional Consequences​

SegmentMajor issuePractical consequence
Ileum / colonHyperchloremic metabolic acidosisThe commonest chronic abnormality; monitor BMP lifelong[2][22][23]
IleumVitamin B12 deficiency / bile salt malabsorptionHigher risk with longer ileal segments; periodic B12 monitoring is reasonable[2][23]
Ileum / colonBone demineralizationChronic acidosis can mobilize bone calcium and contribute to osteoporosis[22][23]
StomachHypochloremic metabolic alkalosisParticularly relevant in patients with renal insufficiency[3][11]
StomachHematuria-dysuria syndromeEspecially troublesome in sensate patients with preserved pelvic sensation[3][11]
JejunumSevere electrolyte derangementHyponatremia, hyperkalemia, and acidosis make jejunum an unattractive and generally avoided segment[2][22]

Malignancy Risk and Surveillance​

What is the actual risk?​

Malignancy after augmentation is uncommon but real. Across heterogeneous studies in a systematic review, the reported probability of malignancy ranged from 0% to 5.5%, with a mean latency near 19–20 years.[25] Adenocarcinoma predominates and often arises at or near the entero-urinary anastomosis.[25][26]

The controversy is whether augmentation itself is independently oncogenic or whether congenital bladder dysfunction, chronic inflammation, stones, and infection already confer part of the risk.[24][27] The practical answer for follow-up is the same: these patients need lifelong vigilance.

Gastrocystoplasty deserves extra concern​

Gastrocystoplasty has a particularly concerning malignancy signal, with multiple series reporting adenocarcinoma arising in augmented reservoirs.[10][28]

Surveillance in practice​

Routine surveillance cystoscopy for every asymptomatic augmented patient remains controversial:

  • AUA/SUFU NLUTD guideline: no routine cystoscopy in asymptomatic patients; perform cystoscopy for gross hematuria, recurrent symptomatic UTI, or suprapubic pain[4]
  • Some centers advocate annual cystoscopy after year 10, but decision analyses and retrospective studies have questioned its effectiveness and cost-effectiveness in asymptomatic patients.[29][30][31]
  • Gastrocystoplasty warrants individualized specialist discussion because of its malignancy signal; these reports do not establish a validated annual cystoscopy schedule for every asymptomatic patient.[3][28]

Postoperative Management and Lifelong Follow-Up​

Patients with bowel-incorporating bladder reconstructions require structured lifelong surveillance.[4]

Core follow-up elements​

  • Annual focused history, examination, and symptom assessment
  • Annual basic metabolic panel
  • Annual urinary tract imaging, usually ultrasound, with additional evaluation when risk or symptoms require it
  • CIC education and adherence review
  • Regular bladder irrigation to clear mucus
  • Monitor vitamin B12 over time when terminal ileum is incorporated; assess additional nutritional risks according to the segment and length used[4][23]

Functional follow-up​

Repeat urodynamics can be helpful when symptoms, leakage, or upper-tract changes raise concern that the augment is no longer low pressure or the outlet strategy is failing.

Red-flag symptoms​

Immediate evaluation is warranted for:

  • New gross hematuria
  • Recurrent unexplained symptomatic UTI
  • Increasing suprapubic pain
  • Difficult catheterization or acute retention
  • Sudden abdominal pain / sepsis suggesting perforation[4][20]

Alternatives to Augmentation​

AlternativeRole
Intradetrusor botulinum toxinUseful before augmentation, but many severely noncompliant bladders remain refractory; repeat treatment is required[4][32]
Ileal conduitA rational alternative for the patient who cannot catheterize reliably, has major comorbidity, or would be poorly served by lifelong augmented-reservoir maintenance[21]
IleovesicostomyIncontinent low-pressure outlet preserving the native bladder; useful in selected NLUTD patients[4]
Sacral neuromodulationConsidered only in selected NLUTD populations; not a substitute for augmentation in severe hostile bladders from complete SCI or spina bifida[4]

Bottom Line for the Reconstructive Surgeon​

Augmentation cystoplasty remains the benchmark bladder-salvage operation for the unsafe, refractory low-capacity bladder. The modern reconstructive decision is less about whether augmentation works — it does — and more about whether the patient is a good candidate for a lifelong bowel-incorporating reservoir with reliable emptying versus an appropriate diversion.[1][4][20][21]

Done well, AC provides durable low-pressure storage, protects renal function, and restores continence for most patients. Done without careful selection or lifelong follow-up, it exposes the patient to stones, metabolic complications, perforation, and late malignancy. That tension is exactly why augmentation belongs at the center of bladder reconstruction rather than at its margin.

Videos​

Laparoscopic Augmentation Cystoplasty
Preeti Urology & Kidney Hospital (2023)
Robotic Augmentation Cystoplasty
Preeti Urology & Kidney Hospital (2024)

References​

1. Cheng PJ, Myers JB. Augmentation cystoplasty in the patient with neurogenic bladder. World J Urol. 2020;38(12):3035-3046. doi:10.1007/s00345-019-02919-z

2. Roth JD, Cain MP. Neuropathic bladder and augmentation cystoplasty. Urol Clin North Am. 2018;45(4):571-585. doi:10.1016/j.ucl.2018.06.005

3. Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012;109(9):1280-1293. doi:10.1111/j.1464-410X.2011.10650.x

4. Ginsberg DA, Boone TB, Cameron AP, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urol. 2021;206(5):1106-1113. doi:10.1097/JU.0000000000002239

5. Stein R, Wiesner C, Beetz R, Schwarz M, Thüroff JW. Urinary diversion in children and adolescents with neurogenic bladder: the Mainz experience. Part I: bladder augmentation and bladder substitution--therapeutic algorisms. Pediatr Nephrol. 2005;20(7):920-925. doi:10.1007/s00467-005-1847-3

6. Ghorai RP, Jain S, Nayak B, et al. Long-term outcomes of augmentation cystoplasty in genitourinary tuberculosis in adults: a 12-year follow-up experience at a tertiary care center. Urology. 2024;189:119-125. doi:10.1016/j.urology.2024.04.031

7. Smith RB, van Cangh P, Skinner DG, Kaufman JJ, Goodwin WE. Augmentation enterocystoplasty: a critical review. J Urol. 1977;118(1 Pt 1):35-39. doi:10.1016/S0022-5347(17)57878-7

8. Shekarriz B, Upadhyay J, Demirbilek S, Barthold JS, González R. Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients. Urology. 2000;55(1):123-128. doi:10.1016/S0090-4295(99)00443-4

9. Sidi AA, Reinberg Y, Gonzalez R. Influence of intestinal segment and configuration on the outcome of augmentation enterocystoplasty. J Urol. 1986;136(6):1201-1204. doi:10.1016/S0022-5347(17)45282-7

10. Vemulakonda VM, Lendvay TS, Shnorhavorian M, et al. Metastatic adenocarcinoma after augmentation gastrocystoplasty. J Urol. 2008;179(3):1094-1096. doi:10.1016/j.juro.2007.10.089

11. Kurzrock EA, Baskin LS, Kogan BA. Gastrocystoplasty: is there a consensus? World J Urol. 1998;16(4):242-250. doi:10.1007/s003450050061

12. Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol. 1989;142(2 Pt 2):505-508. doi:10.1016/S0022-5347(17)38798-0

13. Stöhrer M, Kramer G, Goepel M, et al. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord. 1997;35(7):456-462. doi:10.1038/sj.sc.3100441

14. Diamond DA, Chan IHY, Holland AJA, et al. Advances in paediatric urology. Lancet. 2017;390(10099):1061-1071. doi:10.1016/S0140-6736(17)32282-1

15. Gill IS, Rackley RR, Meraney AM, Marcello PW, Sung GT. Laparoscopic enterocystoplasty. Urology. 2000;55(2):178-181. doi:10.1016/S0090-4295(99)00526-9

16. Barashi NS, Rodriguez MV, Packiam VT, Gundeti MS. Bladder reconstruction with bowel: robot-assisted laparoscopic ileocystoplasty with Mitrofanoff appendicovesicostomy in pediatric patients. J Endourol. 2018;32(S1):S119-S126. doi:10.1089/end.2017.0720

17. Chang JW, Kuo FC, Lin TC, et al. Long-term complications and outcomes of augmentation cystoplasty in children with neurogenic bladder. Sci Rep. 2024;14(1):4214. doi:10.1038/s41598-024-54431-z

18. Venn SN, Mundy AR. Long-term results of augmentation cystoplasty. Eur Urol. 1998;34 Suppl 1:40-42. doi:10.1159/000052275

19. Hoen L, Ecclestone H, Blok BFM, et al. Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: a systematic review. Neurourol Urodyn. 2017;36(7):1685-1702. doi:10.1002/nau.23205

20. Szymanski KM, Misseri R, Whittam B, et al. Additional surgeries after bladder augmentation in patients with spina bifida in the 21st century. J Urol. 2020;203(6):1207-1213. doi:10.1097/JU.0000000000000751

21. Ginsberg DA. The argument for ileal conduit for the poorly compliant bladder in the neurogenic lower urinary tract dysfunction patient refractory to minimally invasive treatment. Neurourol Urodyn. 2026. doi:10.1002/nau.70220

22. Gilbert SM, Hensle TW. Metabolic consequences and long-term complications of enterocystoplasty in children: a review. J Urol. 2005;173(4):1080-1086. doi:10.1097/01.ju.0000155248.57049.4e

23. Roth JD, Koch MO. Metabolic and nutritional consequences of urinary diversion using intestinal segments to reconstruct the urinary tract. Urol Clin North Am. 2018;45(1):19-24. doi:10.1016/j.ucl.2017.09.007

24. Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172(4 Pt 2):1649-1651. doi:10.1097/01.ju.0000140194.87974.56

25. Biardeau X, Chartier-Kastler E, Rouprêt M, Phé V. Risk of malignancy after augmentation cystoplasty: a systematic review. Neurourol Urodyn. 2016;35(6):675-682. doi:10.1002/nau.22775

26. Garnier S, Vendrell J, Boillot B, et al. Malignancy after augmentation enterocystoplasty: a nationwide study of natural history, prognosis and oncogene panel analysis. J Urol. 2020;204(1):136-143. doi:10.1097/JU.0000000000000752

27. Higuchi TT, Granberg CF, Fox JA, Husmann DA. Augmentation cystoplasty and risk of neoplasia: fact, fiction and controversy. J Urol. 2010;184(6):2492-2496. doi:10.1016/j.juro.2010.08.038

28. Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol. 2007;178(4 Pt 2):1771-1774. doi:10.1016/j.juro.2007.05.100

29. Hamid R, Greenwell TJ, Nethercliffe JM, et al. Routine surveillance cystoscopy for patients with augmentation and substitution cystoplasty for benign urological conditions: is it necessary? BJU Int. 2009;104(3):392-395. doi:10.1111/j.1464-410X.2009.08401.x

30. Higuchi TT, Fox JA, Husmann DA. Annual endoscopy and urine cytology for the surveillance of bladder tumors after enterocystoplasty for congenital bladder anomalies. J Urol. 2011;186(5):1791-1795. doi:10.1016/j.juro.2011.07.028

31. Kokorowski PJ, Routh JC, Borer JG, et al. Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis. J Urol. 2011;186(4):1437-1443. doi:10.1016/j.juro.2011.05.065

32. O'Connor RC, Johnson DP, Guralnick ML. Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2020;39(8):2322-2328. doi:10.1002/nau.24490

33. European Association of Urology. EAU Guidelines on Neuro-urology. 2026. Sections 3.4.3.5–3.4.3.7 and 3.7. Official guideline.